Results 21 to 30 of about 115,328 (341)
The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention [PDF]
, 2018 Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it is a potentially painful and debilitating condition that can considerably affect the quality of life of patients ...
Bedogni, Alberto +7 more
core +2 more sources
Pharmacology of bisphosphonates.
British Journal of Clinical Pharmacology, 2019 The biological effects of the bisphosphonates (BPs) as inhibitors of calcification and bone resorption were first described in the late 1960s. In the 50 years that have elapsed since then, the BPs have become the leading drugs for the treatment of ...
S. Cremers +6 more
semanticscholar +1 more source
Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review
BMJ Open, 2019 Objectives This study examined patient adherence and persistence to oral bisphosphonates for the treatment of osteoporosis in real-world settings. Methods A systematic review was completed according to the Preferred Reporting Items for Systematic Reviews
F. Fatoye +3 more
semanticscholar +1 more source
Turkish Journal of Orthodontics, 2009 Bisphosphonates are used with the purpose of preventing bone resorption in some metabolic bone diseases. These drugs have been introduced into clinical use about 30 years ago and widely used in nowadays. As Orthodontic some different researches have been
Fırat Öztürk
doaj +1 more source
Evaluation of trabecular bone changes according to the type of prosthesis in patients using bisphosphonates: a retrospective study [PDF]
Brazilian Oral Research, 2023 The objective of the study was to retrospectively compare the fractal size values calculated in the trabecular bone according to the type of complete removable denture, removable partial denture, and partial fixed prosthesis between patients using ...
Begüm Ünlü Kurşun, Ender Akan
doaj +1 more source
Comparison of osteoporosis pharmacotherapy fracture rates: Analysis of a marketScan® claims database cohort [PDF]
, 2018 Background: Several different classes of medications have been shown to be efficacious at preventing fractures in patients with osteoporosis. No study has compared real world efficacy at preventing fractures between all currently approved medications ...
Fox, Edward J. +5 more
core +2 more sources
Bolʹ, Sustavy, Pozvonočnik, 2012 The paper presents the recent data with the literature review on the controversial issue of the link between chronic administration of bisphosphonates, and atypical femoral shaft fractures.
I.Yu. Golovach
doaj +1 more source
Medication-related osteonecrosis of the jaw: clinical and practical guidelines [PDF]
, 2016 Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, consisting of progressive bone destruction in the maxillofacial region of patients.
Allen +42 more
core +2 more sources
Pharmacy, 2018 Oral bisphosphonates are the first choice of therapy to reduce the risk of osteoporotic fractures. These medications have generally poor oral bioavailability, which may further be reduced by concomitant intake of certain foods and drugs; therefore, it is
Linnea Abramsson, Maria Gustafsson
doaj +1 more source
Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. [PDF]
PLoS ONE, 2011 BACKGROUND: Bisphosphonates and parathyroid hormone (PTH) represent the antiresorptive and anabolic classes of drugs for osteoporosis treatment. Bone mineral density (BMD) is an essential parameter for the evaluation of anti-osteoporotic drugs.
Longxiang Shen +5 more
doaj +1 more source